Dr James Miskin | Chief Technical Officer
Oxford BioMedica

Dr James Miskin, Chief Technical Officer, Oxford BioMedica

Dr James Miskin is Chief Technical Officer at Oxford BioMedica Plc.  James obtained his Ph.D in bacterial molecular biology in 1995 from the University of Leeds, UK. He then worked for over five years as a post‐doctoral research scientist at the UK government‐funded Institute for Animal Health, investigating viral‐host interactions of the haemorrhagic pathogen African Swine Fever Virus.  James then joined Oxford BioMedica (OXB) in December 2000 as a specialist in molecular virology. Since that time he has worked in a number of research and development areas, in particular developing methods to investigate the safety profile of lentiviral vectors, and is a named inventor on several patents in the field.  James has significant experience in GxP assay development, routine testing, manufacturing, manufacturing development and analytical development. In his current role as Chief Technical Officer, he is a member of the company’s senior executive team (SET) with overall leadership responsibility for two teams within the Company: Manufacturing and Manufacturing Development. The Manufacturing team is responsible for routine GMP production, supply chain and oversight of technical programmes with our strategic partners, including Novartis and Sanofi. The Manufacturing development team is responsible for manufacturing process development, technical support, new process introduction and technology transfer (for internal and partnership manufacturing).

Appearances:



Conference Day 1: Thursday 16th May 2019 @ 09:30

(ex vivo) Gene edited therapeutics and (in vivo) gene therapy: how can gene technology be used now and, in the future, to treat and cure diseases in the clinic

  • How does gene editing apply to the clinic?
  • How is it currently being applied?
  • How can we improve delivery of AAVs into the cell?
  • Improving the volume of viral particles: what stages do we need to cover to get to a commercial scale?
  • Moving into larger diseases from rare diseases, what challenges need to be overcome?
  • Risk/benefit acceptance of the general population and the medical system.
  • What is the real risk of CRISPR causing cancer as published by Novartis and KI?
  • How do we want to use it in the future and what challenges need to be overcome to do so? (immunogenicity, off target effects and efficacy, being vigilant with safety profiles, potency and manufacturing, moving towards direct, in vivo [bluebird bio live delivery usingnanoparticles], viral and non-viral)
  • How do you move towards that goal in a way that engages stakeholders? Applications

Conference Day 1: Thursday 16th May 2019 @ 17:05

Series of 10-minute updates from gene therapy organisations followed by a panel discussion on strategically improving issues in vivo gene therapy 

  • In vivo gene therapy – moving away from the bias of AAV  
  • Why the field has accelerated so rapidly catalyzed CAR-T 
  • Solving the problem of high manufacturing costs 
  • AAV vs Lenti platforms pros and cons 
How industry, academia and patient organizations can work together to improve outcomes for patients. 
last published: 21/Mar/19 09:25 GMT

back to speakers

There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.

There is a registration fee to attend the conferences. To visit the exhibition is free.

TO SPONSOR / EXHIBIT

Erica Baeta 
+44 (0)207 092 1152 
erica.baeta@terrapinn.com

TO SPEAK

Jessica Robinson 
t/ +44 (0)207 092 1150 
jessica.robinson@terrapinn.com

TO REGISTER

Issa Mauthoor 
+44 (0)207 092 1257 
issa.mauthoor@terrapinn.com